SAN

79.29

+2.36%↑

UCB

251

+0.36%↑

SHL.DE

36.94

+0.52%↑

ARGX

591

+1.2%↑

VIE

32.39

+2.96%↑

SAN

79.29

+2.36%↑

UCB

251

+0.36%↑

SHL.DE

36.94

+0.52%↑

ARGX

591

+1.2%↑

VIE

32.39

+2.96%↑

SAN

79.29

+2.36%↑

UCB

251

+0.36%↑

SHL.DE

36.94

+0.52%↑

ARGX

591

+1.2%↑

VIE

32.39

+2.96%↑

SAN

79.29

+2.36%↑

UCB

251

+0.36%↑

SHL.DE

36.94

+0.52%↑

ARGX

591

+1.2%↑

VIE

32.39

+2.96%↑

SAN

79.29

+2.36%↑

UCB

251

+0.36%↑

SHL.DE

36.94

+0.52%↑

ARGX

591

+1.2%↑

VIE

32.39

+2.96%↑

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Avatud

26.85 4.47

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

24.95

Max

28.95

Põhinäitajad
By Trading Economics
Sissetulek	-5.4M
Müük	27M
Kasumimarginaal	-20.208
Töötajad	103
EBITDA	1.1M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	-10.85% downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	1. apr 2026

Turustatistika
By TradingEconomics
Turukapital	1.4B
Eelmine avamishind	22.38
Eelmine sulgemishind	26.85

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. märts 2026, 18:58 UTC

Suurimad hinnamuutused turgudel

MDA Space Shares Drop After NASA Shifts Focus to Moon's Surface and Away From Space Station

24. märts 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. märts 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

24. märts 2026, 23:33 UTC

Market Talk

Uudisväärsed sündmused

Gold Rises, Boosted by Dollar Weakness -- Market Talk

24. märts 2026, 23:16 UTC

Market Talk

Venezuelan Opposition Leader Says Oil Output Could Reach 5 Million B/D -- Market Talk

24. märts 2026, 22:40 UTC

Tulu

Shanghai Fosun Pharmaceutical: Results Supported by Higher Rev From Innovative Drugs, Overseas Business >2196.HK

24. märts 2026, 22:40 UTC

Tulu

Shanghai Fosun Pharmaceutical 2025 Net CNY3.37B Vs. Net CNY2.77B >2196.HK

24. märts 2026, 22:40 UTC

Tulu

Shanghai Fosun Pharmaceutical 2025 Rev CNY41.50B Vs. CNY40.91B >2196.HK

24. märts 2026, 21:44 UTC

Market Talk

Global Equities Roundup: Market Talk

24. märts 2026, 21:44 UTC

Market Talk

Sandfire's New Bull Excited by Kalkaroo Copper Deposit -- Market Talk

24. märts 2026, 20:59 UTC

Tulu

Medtronic PLC Cuts FY26 View To Adj EPS $5.50-Adj EPS $5.54 >MDT

24. märts 2026, 20:58 UTC

Uudisväärsed sündmused

Israel Hits Russian-Iranian Weapons Smuggling Route in the Caspian Sea -- WSJ

24. märts 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Energy & Utilities Roundup: Market Talk

24. märts 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

24. märts 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24. märts 2026, 20:25 UTC

Tulu

This Palantir-Linked Drone Stock Was Flying Under the Radar -- Until Now -- Barrons.com

24. märts 2026, 20:15 UTC

Market Talk

Uudisväärsed sündmused

Global Commodities Roundup: Market Talk

24. märts 2026, 20:10 UTC

Market Talk

Canada Mortgage Arrears Linked to Labor Market Performance -- Market Talk

24. märts 2026, 20:10 UTC

Tulu

Worthington Enterprises 3Q Sales $378.7M >WOR

24. märts 2026, 20:10 UTC

Tulu

Worthington Enterprises 3Q Adj EPS 98c >WOR

24. märts 2026, 20:10 UTC

Tulu

Worthington Enterprises 3Q EPS 92c >WOR

24. märts 2026, 19:25 UTC

Market Talk

Uudisväärsed sündmused

Canada Needs Roughly 100 Days to Meet IEA's Oil-Stock Release -- Market Talk

24. märts 2026, 19:06 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Regain Ground As Strikes Continue in Middle East -- Market Talk

24. märts 2026, 18:51 UTC

Market Talk

Uudisväärsed sündmused

U.S. Natural Gas Settles Higher As Oil Futures Gain -- Market Talk

24. märts 2026, 18:40 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

24. märts 2026, 18:40 UTC

Market Talk

Uudisväärsed sündmused

Mideast Conflict to Hobble But Not Derail Canadian Economy -- Market Talk

24. märts 2026, 18:34 UTC

Uudisväärsed sündmused

Oil Production in the Middle East Will Take Months to Come Back, CEO says. Why $100 Oil Could Be Here to Stay. -- Barrons.com

24. märts 2026, 18:27 UTC

Market Talk

Inflation Pickup Could Keep Bank of Mexico on Hold -- Market Talk

24. märts 2026, 18:21 UTC

Market Talk

Uudisväärsed sündmused

Silver Snaps 9-Session Losing Streak -- Market Talk

24. märts 2026, 18:00 UTC

Omandamised, ülevõtmised, äriostud

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

-10.85% langus

12 kuu keskmine prognoos

Keskmine 23 EUR -10.85%

Kõrge 23 EUR

Madal 23 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.